YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...
Rare / orphan disease drugs
Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline
Novartis (NYSE: NVS) announced an agreement to acquire San Diego-based biotech Avidity Biosciences for USD...
Chiesi Group Launches First EB Wound Treatment in China
The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative...
RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that...
Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular‑RNA (circRNA) therapeutic HM2003 Injection...
Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...
Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros
Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license...
Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia
Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining...
Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...
UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis
UCB S.A. (EBR: UCB), a global biopharmaceutical company, announced today that the National Medical Products...
ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease
ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...
Ipsen Launches BYLVAY in China for Rare Liver Disease
France‑based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the official commercial launch of its rare‑disease...
Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA
Biogen Inc. (NASDAQ: BIIB) announced today that the U.S. Food & Drug Administration (FDA) has...
Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Stealth BioTherapeutics’ Forzinity (elamipretide)...
Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development
Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts‑based Alcyone Therapeutics. The deal centers on...
Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...
FDA Unveils RDEP to Accelerate Rare Disease Therapy Development
The U.S. Food and Drug Administration (FDA) today issued the Rare Disease Evidence Principles (RDEP),...
Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration
Enlaza Therapeutics, Inc. and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) today announced a multi‑target drug discovery...
Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...